Artificial Organs

HepaLife Expands Management Team on Heels of Favorable Outcomes of First-of-Its-Kind Bioartificial Liver Device

Published in Hematology Week, May 21st, 2007

HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) is pleased to announce the addition of Dr. Robert Tuttle as Vice President of Research and Development to assist the Company with development of the first-of-its-kind bioartificial liver device, which, in recent weeks, has mimicked key functions of the liver and surpassed major cell biology and biomechanical milestones.

"I'm honored to welcome Dr. Tuttle as Vice President of Research and Development," commented Mr. Frank Menzler, President and CEO of HepaLife Technologies, Inc. "Dr. Tuttle's appointment follows important research and development successes at HepaLife, prompting the expansion of our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hematology Week

Source: Hematology Week (2007-05-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry